2025年2月11日 · Tyvalzi Combipack Injection is a prescription medicine used for the treatment of ischemic stroke. It works by activating specific receptors in the brain that help enhance blood flow and oxygen delivery to the affected brain areas. This helps in …

Sovateltide (Tycamzzi™), a highly selective endothelin-B receptor agonist and synthetic analog of endothelin-1, is being developed by Pharmazz, Inc. as a neural progenitor cell therapeutic agent for the treatment of acute cerebral ischemic stroke (ACIS), hypoxic-ischemic encephalopathy (HIE), spinal cord injuries and Alzheimer's disease.

Sovateltide (development names IRL-1620 and PMZ-1620, [1] sold in India under the brand name Tyvalzi) [2] is a synthetic analog of endothelin-1 that works as a selective endothelin-B receptor agonist. In May 2023, it was approved in India to treat acute ischemic stroke. The drug was developed by Pharmazz. [2]

Tyvalzi™ is a first-in-class drug to treat acute cerebral ischemic stroke, a condition in which the loss of blood supply to the brain prevents brain tissue from receiving oxygen and nutrients, resulting in potential brain damage, neurological deficits, or death. Tyvalzi™ is unique in that its site of action is the neural progenitor cells.

2023年9月14日 · Sovateltide是第一种治疗急性脑缺血性中风的药物，可以在症状出现后24小时内给药。 India是Tyvalzi的第一个全球性领域™ （Sovateltide）正在伊利诺伊州WILLOWBROOK推出，2023年9月14日（GLOBE NEWSWIRE）-Pharmazz，Inc。

2023年9月14日 · Biopharmaceutical company Pharmazz and Sun Pharmaceutical Industries have signed a licence agreement for the marketing of Tyvalzi (Sovateltide) in India. In an increasingly complex prescribing landscape, treatments can be difficult for both patients and healthcare professionals to understand.

2024年7月27日 · Sovateltide (Tyvalzi TM), a first-in-class selective endothelin B receptor agonist, is a valuable new therapy for the treatment of cerebral ischaemic stroke. It promotes neurovascular remodelling, increases cerebral blood flow, has anti-apoptotic activity, protects neural mitochondria, and enhances mitochondrial biogenesis.

2023年9月14日 · Sovateltide (Tyvalzi™), a selective endothelin B receptor agonist, a new first-in-class drug recently approved for treating cerebral ischemic stroke, can be administered up to 24 hours post...

The Indian multinational pharmaceutical company, Sun Pharmaceutical has entered into a licence agreement with US-based Pharmazz Inc. to commercialise Tyvalzi (Sovateltide), in India. Sovateltide, developed by the US biopharmaceutical company, is designed for the treatment of cerebral ischemic stroke.

2023年9月18日 · Leading Indian drugmaker Sun Pharmaceutical Industries (BSE: 524715) has entered into a license agreement with US privately-held biopharma Pharmazz to commercialize a first-in-class innovative drug, Tyvalzi (sovateltide) in …